ProCE Banner Activity


Optimizing Precision Medicine for Patients With Lung and Thyroid Cancer: Guidance for the Multidisciplinary Team


Expert faculty discuss how the multidisciplinary team can work together to optimize precision medicine for patients with lung and thyroid cancer.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: December 14, 2023

Expiration: December 13, 2024



Vamsidhar Velcheti

Vamsidhar Velcheti, MD

Professor of Medicine
NYU Grossman School of Medicine
Medical Director
Thoracic Oncology Program
Laura and Isaac Perlmutter Cancer Center
An NCI-designated Comprehensive Cancer Center
New York, New York 

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Lilly.


Target Audience

This program is intended for medical oncologists, pathologists, surgeons, interventional radiologists, pharmacists, nurse practitioners, physician associates, nurses, and other healthcare professionals who care for patients with lung and thyroid cancer.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners to optimize precision medicine approaches for patients with lung or thyroid cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Order appropriate guideline-recommended comprehensive genomic testing prior to treatment initiation to guide individualized therapy planning for patients with advanced or metastatic NSCLC and thyroid cancer

  • Apply clinical data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC and thyroid cancer and RET inhibition in RET-altered lung and thyroid cancer

  • Formulate timely strategies for integrating TRK and RET inhibitors into the management of eligible patients with advanced or metastatic NSCLC and thyroid cancer, based on expert recommendations and oncogenic gene fusion status

  • Engage patients with advanced or metastatic NSCLC and thyroid cancer in shared decision-making to integrate patient preferences and goals into treatment planning


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Vamsidhar Velcheti, MD

Professor of Medicine
NYU Grossman School of Medicine
Medical Director
Thoracic Oncology Program
Laura and Isaac Perlmutter Cancer Center
An NCI-designated Comprehensive Cancer Center
New York, New York 

Vamsidhar Velcheti, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Janssen, Merck, Sanofi.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below.

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, CTI, DSI, Gilead, Lilly, MorphoSys, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 14, 2023, through December 13, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement


In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-317-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until December 13, 2024. PAs should only claim credit commensurate with the extent of their participation.